Nevanimibe

Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1].

Product Specifications

CAS Number

[133825-80-6]

Product Name Alternative

PD-132301; ATR-101

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Acyltransferase; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Nevanimibe.html

Purity

98.99

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(NCC1(C2=CC=C(N(C)C)C=C2)CCCC1)NC3=C(C(C)C)C=CC=C3C(C)C

Molecular Formula

C27H39N3O

Molecular Weight

421.62

Precautions

H302, H315, H319, H335

References & Citations

[1]LaPensee CR, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016 May;157 (5) :1775-88.